SCS Capital Management LLC Makes New Investment in Dianthus Therapeutics, Inc. $DNTH

SCS Capital Management LLC acquired a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 9,375 shares of the company’s stock, valued at approximately $914,000.

Other large investors also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Dianthus Therapeutics in the 2nd quarter worth $27,000. First Horizon Corp bought a new stake in Dianthus Therapeutics during the first quarter valued at about $32,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Dianthus Therapeutics in the fourth quarter valued at about $40,000. Russell Investments Group Ltd. purchased a new position in shares of Dianthus Therapeutics in the third quarter valued at about $64,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after acquiring an additional 3,317 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $115.96 on Monday. The stock has a 50 day moving average price of $97.47 and a 200-day moving average price of $83.07. Dianthus Therapeutics, Inc. has a one year low of $19.84 and a one year high of $116.47. The company has a market capitalization of $6.34 billion, a P/E ratio of -27.94 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 31,249 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the sale, the executive vice president directly owned 31,249 shares in the company, valued at $3,157,086.47. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Marino Garcia sold 166,000 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer owned 65,292 shares in the company, valued at $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 284,306 shares of company stock valued at $29,289,369 over the last ninety days. Corporate insiders own 3.02% of the company’s stock.

Analysts Set New Price Targets

DNTH has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Truist Financial boosted their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wedbush upped their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.